Harm reduction, hepatitis C and opioid pharmacotherapy: An opportunity for integrated hepatitis C virus-specific harm reduction

Drug and Alcohol Review

Volumn 26, Issue 4, 2007, Pages 437-443

  Hallinan, Richard ^a   Byrne, Andrew ^a   Dore, Gregory J ^b  

^a Byrne Surgery   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; AUSTRALIA; HARM REDUCTION; HEALTH PROMOTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; METHODOLOGY; OPIATE ADDICTION; PREVENTIVE HEALTH SERVICE; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH SERVICE; RISK REDUCTION; SUBSTANCE ABUSE; VIROLOGY;

ANALGESICS, OPIOID; HARM REDUCTION; HEALTH PROMOTION; HEPACIVIRUS; HEPATITIS C; HUMANS; METHADONE; NEEDLE-EXCHANGE PROGRAMS; NEW SOUTH WALES; OPIOID-RELATED DISORDERS; PUBLIC HEALTH PRACTICE; RISK REDUCTION BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 34250318455     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230701373933     Document Type: Article

References (39)

1. Wodak A, Crofts N. HIV revisited: preventing the spread of blood-borne viruses among injecting drug users. Aust J Public Health 1994;18:239-41.
2. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003;26:171-84.
3. Kaldor JM, Dore GJ, Correll PK. Public health challenges in hepatitis C virus infection. J Gastroenterol Hepatol 2000;15(Suppl):E83-90.
4. Byrne AJ3 Wodak A. Census of patients receiving methadone treatment in a general practice. Addict Res 1996;3: 341-9.
5. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997;92:999-1005.
6. Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993;159:237-41.
7. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust 1997;167:17-20.
8. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. Aust NZ J Public Health 2004;28: 576-8.
9. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005;20:1082-6.
10. Kapadia F, Latka MH, Hagan H, et al. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health 2007;84:99-115.
11. Strain EC, Bigelow GE, Liebson IA, Sdtzer ML. Moderatevs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999;281: 1000-5.
12. Hallinan R, Ray J, Byrne A, Agho K, Attia J. Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis. Drug Alcohol Depend 2006;81:129-36.
13. Salsitz EA, Joseph H, Frank B, et al. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice - a summary report (1983-1998). Mt Sinai J Med 2000;67:388-97.
14. Schmitz JM, Rhoades HM, Elk R, Creson D, Hussein I, Grabowski J. Medication take-home doses and contingency management. Exp Clin Psychopharmacol 1998;6: 162-8.
15. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998;88:34-9.
16. Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep 1998;113(Suppl 1):107-15.
17. Brady TM, Salvucci S, Sverdlov LS, et al. Methadone dosage and retention: an examination of the 60 mg/day threshold. J Addict Dis 2005;24:23-47.
18. D'Aunno T, Pollack HA. Changes in methadone treatment practices: results from a national panel study, 1988-2000. JAMA2002;288:850-6.
19. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005;77:81-6.
20. Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005;25:18-32.
21. Jauffret-Roustide M, Emmanuelli J, Desenclos JC. [Limited impact of the harm-reduction policy on HCV among drug-users. The ANRS - Coquelicot survey example]. Rev Epidemiol Sante Publique 2006;54(Spec 1): 1S53-9.
22. Weaver MF, Cropsey KL, Fox SA. HCV prevalence in methadone maintenance: self-report versus serum test. Am J Health Behav 2005;29:387-94.
23. Mark KE, Murray PJ, Callahan DB, Gunn RA. Medical care and alcohol use after testing hepatitis C antibody positive at STD clinic and HIV test site screening programs. Public Health Rep 2007;122:37-43.
24. Campbell JV, Hagan H, Latka MH et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006;81:259-65.
25. Dore G. Therapy decision-making for people with chronic hepatitis C. In: Crofts N, Dore G, Locarnini S, eds. Hepatitis C: an Australian perspective. Melbourne: IP Communications, 2001:178-9.
26. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007;88: 49-53.
27. Dalgard 3O, Bjoro K, Hellum K. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002;8:45-9.
28. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004;39:1540-3.
29. Hagan H, Strauss SM, Astone JM, Des Jarlais DC. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clin Infect Dis 2005;40(Suppl 5):S297-303.
30. Verrando R, Robaeys G, Mathei C, Buntinx F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastroenterol Belg 2005;68:81-5.
31. Strauss SM, Astone JM, Des Jarlais DC, Hagan H. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. AIDS Patient Care STDS 2005;19:78-88.
32. Clanon KA, Johannes Mueller J, Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 2005;40(Suppl 5):S362-6.
33. Gunn RA, Lee MA, Callahan DB, Gonzales P, Murray PJ, Margolis HS. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program. Am J Prev Med 2005;29:27-33.
34. Edlin BR, Kresina TF, Raymond DB. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005;40(Suppl 5):S276-85.
35. Budd J, Robertson R. Hepatitis C and general practice: the crucial role of primary care in stemming the epidemic. Br J Gen Pract 2005;55:259-60.
36. Kresina TF, Khalsa J, Cesari H, Francis H. Hepatitis C virus infection and substance abuse: medical management and developing models of integrated care - an introduction. Clin Infect Dis 2005;40(Suppl 5):S259-62.
37. Flanigan TP, Taylor LE, Mitty JA. Use of community-based, directly observed therapy for HIV infection: lessons learned for treatment of hepatitis C virus infection. Clin Infect Dis 2005;40(Suppl 5):S346-8.
38. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005;40(Suppl 5):S33-45.
39. Friedmann PD, D'Aunno TA, Jin L, Alexander JA. Medical and psychosocial services in drug abuse treatment: do stronger linkages promote client utilization? Health Serv Res 2000;35:443-65.